Newly launched include generics of Spiriva HandiHaler, Forteo, Livalo and Farxiga.
Lupin has launched its generic version of Spiriva HandiHaler. Lupin’s tiotropium bromide inhalation powder capsule is approved to treat patients with chronic obstructive pulmonary disease (COPD).
Additionally, the FDA has approved several generic products developed by Lupin. Pitavastatin tablets, 1 mg, 2 mg, and 4 mg and a generic equivalent of Livalo, was approved to treat adults with primary hyperlipidemia, and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia.
Lupin has also received tentative approval from the FDA for dapagliflozin tablets, 5 mg, and 10 mg to market a generic equivalent of Farxiga, which is used to treat patients with diabetes. Both products will be manufactured at Lupin’s Pithampur facility in India.
Lupin also received FDA approval of ganirelix acetate injection, 250 mcg/0.5 mL single-dose prefilled syringe, which is used for infertility treatment. It will be manufactured at Lupin’s Nagpur facility in India.
In other generic news:
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More